Table 1.

Baseline characteristics of patients with class V+IV LNa

CharacteristicMultitarget Therapy Group (n = 20)IVCY Group (n = 20)P
Male:female4:162:180.657
Biopsy age (yr; mean ± SD)27.2 ± 7.130.6 ± 4.60.084
Duration of SLE (mo)36.0 (12.7 to 72.0)44.0 (4.7 to 78.0)0.924
Duration of LN (mo)30.0 (4.5 to 60.0)26.0 (3.7 to 58.7)0.692
SLE-DAI (mean ± SD)14.9 ± 4.014.0 ± 2.40.401
Urine protein (g/24 h; mean ± SD)4.41 ± 1.954.10 ± 1.200.554
Urine RBC (×104/ml)37.5 (3.5 to 106.2)40.0 (10.0 to 161.2)0.945
Scr (mg/dl; mean ± SD)0.87 ± 0.210.89 ± 0.300.797
eCcr (ml/min per 1.73 m2; mean ± SD)98.6 ± 23.596.6 ± 26.30.795
Renal insufficiency (Scr >1.24 mg/dl; n [%])1 (5.0)2 (10.0)1.000
Albumin (g/L; mean ± SD)23.9 ± 5.724.6 ± 3.90.665
ANA positive (n [%])18 (90.0)19 (95.0)1.000
Anti-dsDNA positive (n [%])12 (60.0)12 (60.0)1.000
Serum C3 <0.79 g/L (n [%])20 (100.0)19 (95.0)1.000
Pathological active index (mean ± SD)9.8 ± 4.28.0 ± 3.70.148
Pathological chronic index (mean ± SD)1.3 ± 0.81.4 ± 0.70.687
Proportion of glomeruli affected by proliferative lesions (%, mean ± SD)96.1 ± 6.493.2 ± 9.90.293
Proportion of glomeruli affected by membranous lesions (involving >50% of the tuft; %, mean ± SD)59.8 ± 6.660.1 ± 7.30.893
Previous treatment with CTX or MMF (n [%])14 (70.0)12 (60.0)0.507
ACEI or ARB used (n [%])9 (45.0)11 (55.0)0.527
  • a ACEI, angiotensin-converting enzyme inhibitor; ANA, antinuclear antibody; ARB, angiotensin II receptor blocker; DAI, disease active index; eCcr, estimated creatinine clearance rate; Scr, serum creatinine.